AI biomarker may reveal who responds to esophageal cancer immunotherapy

NCT ID NCT07745322

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This trial tests whether a new AI-driven biomarker, called the Microbial-Sensory Coupling (MSC) index, can predict how well patients with esophageal squamous cell carcinoma respond to anti-PD-1 immunotherapy. The biomarker measures the spatial relationship between a specific bacterium inside tumors and certain host cells. Researchers will analyze pre-treatment tumor biopsies from 270 patients to see if the MSC index can distinguish responders from non-responders and predict survival outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MSC index (a digital pathology biomarker measuring spatial proximity between Campylobacter gracilis and TAAR1+ tumor cells)
What this could lead to
If validated, this biomarker could help doctors predict which esophageal cancer patients will benefit from immunotherapy, sparing others from unnecessary side effects.
What could go wrong
The trial is early and the biomarker is experimental. It may not accurately predict responses in all patients, and the results may not generalize beyond this specific cancer type.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Peking University Cancer Hospital & Institute

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.